Compounds designed to inhibit the HIV-1 protease are in final stages of testing. But significant questions about supply and efficacy need to be answered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steele, F. AIDS drugs lurch towards market. Nat Med 1, 285–286 (1995). https://doi.org/10.1038/nm0495-285
Issue Date:
DOI: https://doi.org/10.1038/nm0495-285